Virological outcome at week 48 of three recommended first-line regimens using ultrasensitive viral load and plasma drug assay

• Published in: Journal of antimicrobial chemotherapy 2014-10, Vol.69 (10), p.2819-2825
• Main Authors: Charpentier, Charlotte, Choquet, Marion, Joly, Véronique, Yeni, Patrick, Visseaux, Benoit, Caseris, Marion, Brun-Vézinet, Françoise, Yazdanpanah, Yazdan, Peytavin, Gilles, Descamps, Diane, Landman, Roland
• Format: Article
• Language: English
• Subjects: Adult; Anti-HIV Agents - pharmacology; Anti-HIV Agents - therapeutic use; Antiretroviral drugs; Bioassays; CD4 Lymphocyte Count; Cross-Sectional Studies; Drug Monitoring; Drug Resistance, Viral - genetics; Female; Genotype; HIV; HIV Infections - drug therapy; HIV Infections - immunology; HIV Infections - virology; HIV-1 - drug effects; HIV-1 - genetics; Human immunodeficiency virus; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Risk Factors; Time Factors; Treatment Outcome; Viral Load; Virology
• ISSN: 0305-7453; 1460-2091
• DOI: 10.1093/jac/dku211

To describe the virological and pharmacological outcomes of three different recommended once-daily first-line regimens in a cross-sectional analysis within an observational cohort using ultra-sensitive HIV quantification. We enrolled all HIV-1-infected patients who initiated tenofovir/emtricitabine with efavirenz, darunavir/ritonavir or atazanavir/ritonavir as a first-line regimen between 1 November 2010 and 30 June 2012. An ultrasensitive viral load (VL) assay was performed and plasma drug concentrations at 24 h (C24) were determined at Week (W) 4, W12, W24, W36 and W48. Sixty patients initiated efavirenz, 81 darunavir/ritonavir and 27 atazanavir/ritonavir. A higher proportion of patients with a VL >100 000 copies/mL received darunavir/ritonavir (P = 0.022). At W48, 89%, 85% and 88% of the patients had a VL